cyclohexanol has been researched along with Anxiety in 65 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (6.15) | 18.2507 |
| 2000's | 30 (46.15) | 29.6817 |
| 2010's | 30 (46.15) | 24.3611 |
| 2020's | 1 (1.54) | 2.80 |
| Authors | Studies |
|---|---|
| Cinar, R; Gao, B; Godlewski, G; Gunduz-Cinar, O; Herrerias, A; Iyer, MR; Kunos, G; Lin, Y; Santos-Molina, L; Wood, CM; Zawatsky, CN | 1 |
| Bedse, G; Gaulden, AD; Hartley, ND; Kingsley, PJ; Marnett, LJ; Neale, E; Patel, S; Patrick, TA; Plath, N; Uddin, MJ | 1 |
| Bortolato, M; Tambaro, S; Tomasi, ML | 1 |
| Assié, MB; Auclair, AL; Bardin, L; Cussac, D; Depoortère, R; Heusler, P; Marien, M; Martel, JC; Newman-Tancredi, A; O'Connor, JA | 1 |
| Carrasco, GA; Franklin, JM | 1 |
| Asarnow, JR; Birmaher, B; Brent, DA; Clarke, GN; Emslie, GJ; He, J; Hilton, RC; Keller, MB; Mansoor, B; Mayes, T; Porta, G; Rengasamy, M; Ryan, N; Shamseddeen, W; Wagner, KD | 1 |
| Bhandary, RP; Munoli, RN; Praharaj, SK; Selvaraj, AG | 1 |
| Charoenphandhu, J; Charoenphandhu, N; Lapmanee, S | 1 |
| Carrasco, GA; Franklin, JM; Mathew, M | 1 |
| Auinger, P; Christine, CW; Factor, SA; Juncos, J; Leentjens, AF; Lyness, JM; Marsh, L; McDonald, W; Moonen, AJ; Panisset, M; Pfeiffer, R; Richard, IH; Rottenberg, D; Serrano Ramos, C; Shulman, L; Singer, C; Slevin, J; Wijers, A | 1 |
| Bullangpoti, V; Kaewwongse, M; Pupa, P; Sanesuwan, K | 1 |
| Fayyad, RS; Guico-Pabia, CJ; Kornstein, SG | 1 |
| Filippov, G; Gislum, M; Montgomery, S; Wang, G | 1 |
| Arnow, BA; Blasey, C; Etkin, A; Kulkarni, J; Luther, JF; Palmer, DM; Rekshan, W; Rush, AJ; Schatzberg, AF; Williams, LM | 1 |
| McMahon, FJ | 1 |
| Garg, R; Kumar, A | 1 |
| Ambrosio, E; Borcel, E; Botreau, F; Del Olmo, N; García-Lecumberri, C; Higuera-Matas, A; Miguéns, M; Pérez-Alvarez, L | 1 |
| Garg, R; Gaur, V; Kumar, A; Kumar, P | 2 |
| Anghelescu, IG; Dierkes, W; Loeschmann, PA; Schmitt, AB; Volz, HP | 1 |
| Kim, JH; Kim, JJ; Kim, S; Lee, H; Lee, JH; Min, BH; Rhee, JC; Rhee, PL; Son, HJ; Suh, YJ | 1 |
| Jiang, Q; Ninan, PT; Tourian, KA | 1 |
| Arnold, JC; Boucher, AA; Huang, X; Hunt, GE; Karl, T; McGregor, IS; Micheau, J | 1 |
| Katiyar, S; Kukade, G; Mahesh, R; Pandey, DK; Rudra, A; Viyogi, S | 1 |
| Arnold, JC; Dielenberg, RA; McGregor, IS | 1 |
| Bacq, A; Balasse, L; Biala, G; Chevarin, C; Gardier, AM; Gautron, S; Giros, B; Guiard, B; Hamon, M; Louis, F; Martres, MP; Schinkel, A; Vialou, V | 1 |
| Almela, P; Aracil-Fernández, A; Manzanares, J | 1 |
| Clarke, G; Clarke, N; Cryan, JF; Desbonnet, L; Dinan, TG; Gogos, JA; Karayiorgou, M; O'Leary, C; O'Tuathaigh, CM; Petit, E; Tighe, O; Waddington, JL; Walsh, J | 1 |
| Charoenphandhu, J; Charoenphandhu, N; Krishnamra, N; Lapmanee, S | 1 |
| Aquino, TD; Lohoff, FW; Multani, PK; Narasimhan, S; Rickels, K | 1 |
| Archer, DF; Bao, W; Cheng, RJ; Constantine, G; Dupont, C; Pickar, JH; Racketa, J | 1 |
| Delagrange, P; Elizalde, N; García-García, AL; Tordera, RM; Venzala, E | 1 |
| Chattarji, S; Cravatt, BF; Filipski, SB; Hill, MN; Hillard, CJ; Iverson, M; Keith, JM; Kumar, SA; McEwen, BS; Stuhr, KL | 1 |
| Lutz, B; Purrio, M; Rey, AA; Viveros, MP | 1 |
| Gibson-Helm, M; Sayakhot, P; Teede, HJ; Vincent, A | 1 |
| Entsuah, R; Hackett, D; Silverstone, PH | 1 |
| Biscaia, M; Fernández, B; Guaza, C; Marco, E; Marín, S; Rubio, M; Schmidhammer, H; Viveros, MP | 1 |
| Ak, I; Aksu, G; Sayar, K; Tosun, M | 1 |
| File, SE; Genn, RF; Marco, EM; Tucci, S; Viveros, MP | 1 |
| File, SE; Genn, RF; Parikh, S; Tucci, S | 1 |
| Mallet, PE; McGregor, IS; O'Shea, M; Singh, ME | 1 |
| Liappas, J; Paparrigopoulos, T; Rabavilas, A; Tzavellas, E | 1 |
| de Guzman, MH; Goldberg, I; Ong, PY; Thiagalingam, S | 1 |
| Boulet, JM; Chaffer, SM; Elsemore, DA; Gottshall, SL; Harrison, JE; Koetzner, L; Lee, G; Mark, L; Miller, W; Pearson, MS; Rabadi, L; Rotshteyn, Y; Shan, S; Tafesse, L; Toth, M; Turchin, PI; Valenzano, KJ; Whiteside, GT | 1 |
| Bourin, M; Hascoët, M; Nic Dhonnchadha, BA; Ripoll, N; Sébille, V | 1 |
| Bourin, M; Hascoët, M; Massé, F | 1 |
| Hayase, T; Yamamoto, K; Yamamoto, Y | 1 |
| Ahokas, A; Bradwejn, J; Emilien, G; Salinas, E; Stein, DJ; Whitaker, T | 1 |
| Peres, MF; Vieira, DS | 1 |
| Mallet, PE; McGregor, IS; O'Shea, M | 1 |
| Akgoz, S; Akkaya, C; Eker, SS; Kirli, S; Sivrioglu, EY | 1 |
| Dhir, A; Kulkarni, SK | 1 |
| Aparicio, N; De Boer, WA; Jansen, JB; Laheij, RJ; Tan, AC; Van den Hazel, S; van Kerkhoven, LA; Witteman, BJ | 1 |
| Blanchard, C; Bourin, M; Danjou, P; Hackett, D; Lecrubier, Y; Moon, CA; Schifano, F | 1 |
| Chitra, R; Entsuah, R; Rudolph, RL | 1 |
| Boyd, IW | 1 |
| Albano, D; Amchin, J; Klockowski, PM; Taylor, KP; Zarycranski, W | 1 |
| Ninan, PT | 1 |
| Perry, CM; Wellington, K | 1 |
| Arévalo, C; de Miguel, R; Hernández-Tristán, R | 1 |
| Morrow, TJ | 1 |
| Berndt, ER; Crown, WH; Finkelstein, SN; Ling, D; Wan, GJ | 1 |
| Biggio, G; Dazzi, L; Ladu, S; Seu, E; Vacca, G; Vignone, V | 1 |
6 review(s) available for cyclohexanol and Anxiety
| Article | Year |
|---|---|
The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo-controlled studies.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Humans; Randomized Controlled Trials as Topic | 2014 |
Analysis of the effect of desvenlafaxine on anxiety symptoms associated with major depressive disorder: pooled data from 9 short-term, double-blind, placebo-controlled trials.
Topics: Adult; Antidepressive Agents; Anxiety; Clinical Trials, Phase III as Topic; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Female; Humans; Male; Middle Aged; Outpatients; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
A meta-analysis of the effects of venlafaxine on anxiety associated with depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Cyclohexanols; Depressive Disorder; Female; Humans; Male; Psychiatric Status Rating Scales; Venlafaxine Hydrochloride | 1998 |
Use of venlafaxine in other psychiatric disorders.
Topics: Anxiety; Attention Deficit Disorder with Hyperactivity; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Fibromyalgia; Humans; Obsessive-Compulsive Disorder; Panic Disorder; Phobic Disorders; Selective Serotonin Reuptake Inhibitors; Trichotillomania; Venlafaxine Hydrochloride | 2000 |
Venlafaxine extended-release: a review of its use in the management of major depression.
Topics: Antidepressive Agents, Second-Generation; Anxiety; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Interactions; Fluoxetine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2001 |
The pharmacoeconomics of venlafaxine in depression.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety; Cost-Benefit Analysis; Cyclohexanols; Depression; Drug Utilization Review; Humans; Managed Care Programs; Selective Serotonin Reuptake Inhibitors; United States; Venlafaxine Hydrochloride | 2001 |
13 trial(s) available for cyclohexanol and Anxiety
| Article | Year |
|---|---|
Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression.
Topics: Adolescent; Anxiety; Attention Deficit and Disruptive Behavior Disorders; Behavioral Symptoms; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Cyclohexanols; Depressive Disorder, Treatment-Resistant; Fluoxetine; Humans; Paroxetine; Remission Induction; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
Topics: Adolescent; Adult; Aged; Anxiety; Asia; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Quality of Life; Selective Serotonin Reuptake Inhibitors; Sulfides; Venlafaxine Hydrochloride; Vortioxetine; Young Adult | 2015 |
Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial.
Topics: Adult; Antidepressive Agents; Anxiety; Citalopram; Cyclohexanols; Depressive Disorder; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Outpatients; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2015 |
Efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial.
Topics: Adult; Anxiety; Chest Pain; Chi-Square Distribution; Cross-Over Studies; Cyclohexanols; Delayed-Action Preparations; Depression; Double-Blind Method; Esophageal Diseases; Esophageal pH Monitoring; Female; Humans; Male; Manometry; Placebos; Psychiatric Status Rating Scales; Quality of Life; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Statistics, Nonparametric; Surveys and Questionnaires; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
Variation in the catechol-O-methyltransferase (COMT) gene and treatment response to venlafaxine XR in generalized anxiety disorder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Anxiety; Catechol O-Methyltransferase; Cyclohexanols; Female; Gene Frequency; Genotype; Humans; Male; Middle Aged; Mutation; Pharmacogenetics; Venlafaxine Hydrochloride; Young Adult | 2012 |
Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms.
Topics: Adult; Affective Symptoms; Aged; Anger; Anxiety; Back Pain; Confusion; Cyclohexanols; Depression; Desvenlafaxine Succinate; Double-Blind Method; Fatigue; Female; Hot Flashes; Humans; Hyperhidrosis; Irritable Mood; Menopause; Middle Aged; Neurotransmitter Uptake Inhibitors; Patient Satisfaction; Sexual Behavior; Surveys and Questionnaires | 2013 |
Two items on the Hamilton Depression rating scale are effective predictors of remission: comparison of selective serotonin reuptake inhibitors with the combined serotonin/norepinephrine reuptake inhibitor, venlafaxine.
Topics: Adolescent; Adult; Affect; Aged; Aged, 80 and over; Anxiety; Cyclohexanols; Depressive Disorder; Female; Humans; Male; Middle Aged; Placebos; Predictive Value of Tests; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Venlafaxine treatment of fibromyalgia.
Topics: Adrenergic Uptake Inhibitors; Adult; Anxiety; Cyclohexanols; Depression; Female; Fibromyalgia; Humans; Pain; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2003 |
Mirtazapine and venlafaxine in the management of collateral psychopathology during alcohol detoxification.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Central Nervous System Depressants; Cyclohexanols; Depressive Disorder; Ethanol; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Patient Dropouts; Psychiatric Status Rating Scales; Socioeconomic Factors; Substance Withdrawal Syndrome; Venlafaxine Hydrochloride | 2005 |
Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study.
Topics: Adult; Analysis of Variance; Anxiety; Capsules; Cholesterol; Cyclohexanols; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Electrocardiography; Fear; Female; Heart Rate; Humans; Male; Panic Disorder; Patient Compliance; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Administration Schedule; Drug Evaluation; Female; Follow-Up Studies; Humans; Male; Middle Aged; Morpholines; Psychiatric Status Rating Scales; Reboxetine; Severity of Illness Index; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Anxiety; Cyclohexanols; Depression; Double-Blind Method; Dyspepsia; Female; Humans; Male; Middle Aged; Placebos; Quality of Life; Venlafaxine Hydrochloride | 2008 |
Efficacy of venlafaxine in depressive illness in general practice.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety; Cyclohexanols; Depression; Double-Blind Method; Family Practice; Female; Humans; Imipramine; Male; Middle Aged; Placebo Effect; Prospective Studies; Social Adjustment; Treatment Outcome; Venlafaxine Hydrochloride | 1997 |
46 other study(ies) available for cyclohexanol and Anxiety
| Article | Year |
|---|---|
Effects of a Peripherally Restricted Hybrid Inhibitor of CB1 Receptors and iNOS on Alcohol Drinking Behavior and Alcohol-Induced Endotoxemia.
Topics: Alcohol Drinking; Animals; Anxiety; Behavior, Animal; Cannabinoid Receptor Antagonists; Catalepsy; Cyclohexanols; Elevated Plus Maze Test; Endotoxemia; Endotoxins; Ethanol; Gastrointestinal Tract; Hypothermia, Induced; Mice, Inbred C57BL; Nitric Oxide Synthase Type II; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Stereoisomerism; Sulfonamides | 2021 |
Functional Redundancy Between Canonical Endocannabinoid Signaling Systems in the Modulation of Anxiety.
Topics: Adaptation, Ocular; Animals; Anti-Anxiety Agents; Anxiety; Arachidonic Acids; Benzodioxoles; Brain; Cannabinoid Receptor Agonists; Cyclohexanols; Disease Models, Animal; Dronabinol; Endocannabinoids; Excitatory Postsynaptic Potentials; Glycerides; Heterocyclic Compounds, 1-Ring; Locomotion; Male; Mice; Mice, Inbred ICR; Piperidines; Polyunsaturated Alkamides; Pyridines; Signal Transduction | 2017 |
Long-term CB₁ receptor blockade enhances vulnerability to anxiogenic-like effects of cannabinoids.
Topics: Animals; Anxiety; Behavior, Animal; Brain; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Cyclohexanols; Dose-Response Relationship, Drug; Down-Regulation; Drug Interactions; Male; Mice; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Up-Regulation | 2013 |
Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety.
Topics: Adrenergic Uptake Inhibitors; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Behavior, Animal; Cerebral Cortex; Cyclohexanols; Cyclopropanes; Depression; Dopamine; Duloxetine Hydrochloride; Humans; Male; Mice; Milnacipran; Motor Activity; Neurotransmitter Transport Proteins; Norepinephrine; Rats; Serotonin; Synaptosomes; Thiophenes; Venlafaxine Hydrochloride | 2013 |
G-protein receptor kinase 5 regulates the cannabinoid receptor 2-induced up-regulation of serotonin 2A receptors.
Topics: Analgesics; Animals; Anxiety; Arrestins; beta-Arrestin 2; beta-Arrestins; Calcium; Cell Culture Techniques; Cyclohexanols; G-Protein-Coupled Receptor Kinase 5; Humans; Lentivirus; Male; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase 3; Models, Biological; Nerve Tissue Proteins; Neurons; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB2; Receptor, Serotonin, 5-HT2A; RNA Interference; Schizophrenia; Up-Regulation | 2013 |
Desvenlafaxine-induced worsening of hypertension.
Topics: Antidepressive Agents; Anxiety; Cyclohexanols; Desvenlafaxine Succinate; Female; Humans; Hypertension; Middle Aged | 2013 |
Beneficial effects of fluoxetine, reboxetine, venlafaxine, and voluntary running exercise in stressed male rats with anxiety- and depression-like behaviors.
Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Anxiety; Cyclohexanols; Depression; Disease Models, Animal; Fluoxetine; Food Preferences; Male; Maze Learning; Morpholines; Physical Conditioning, Animal; Rats; Rats, Wistar; Reboxetine; Restraint, Physical; Running; Stress, Psychological; Sucrose; Swimming; Venlafaxine Hydrochloride | 2013 |
Cannabinoid-induced upregulation of serotonin 2A receptors in the hypothalamic paraventricular nucleus and anxiety-like behaviors in rats.
Topics: Animals; Anxiety; Behavior, Animal; Cannabinoid Receptor Antagonists; Cannabinoids; Cyclohexanols; Male; Paraventricular Hypothalamic Nucleus; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Up-Regulation | 2013 |
Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease.
Topics: Aged; Antidepressive Agents; Anxiety; Cyclohexanols; Datasets as Topic; Depression; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Parkinson Disease; Paroxetine; Predictive Value of Tests; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Severity of Illness Index; Venlafaxine Hydrochloride | 2014 |
Essential oil compounds as stress reducing agents in rats.
Topics: Acyclic Monoterpenes; Animals; Anxiety; Behavior, Animal; Cyclohexanols; Eucalyptol; Female; Humans; Male; Monoterpenes; Oils, Volatile; Plant Oils; Rats; Stress, Physiological; Thymol | 2013 |
Clinically Useful Genetic Markers of Antidepressant Response: How Do We Get There From Here?
Topics: Antidepressive Agents; Anxiety; Citalopram; Cyclohexanols; Depressive Disorder; Depressive Disorder, Major; Female; Humans; Male; Sertraline | 2015 |
A role of nitric oxide mechanism involved in the protective effects of venlafaxine in sleep deprivation.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Arginine; Behavior, Animal; Cyclohexanols; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Lipid Peroxidation; Maze Learning; Methylene Blue; Mice; Motor Activity; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitroprusside; Reaction Time; Sleep Deprivation; Venlafaxine Hydrochloride | 2008 |
Chronic periadolescent cannabinoid treatment enhances adult hippocampal PSA-NCAM expression in male Wistar rats but only has marginal effects on anxiety, learning and memory.
Topics: Animals; Anxiety; Cannabinoids; Corticosterone; Cues; Cyclohexanols; Enzyme-Linked Immunosorbent Assay; Estradiol; Female; Hippocampus; Long-Term Potentiation; Male; Maze Learning; Memory; Neural Cell Adhesion Molecules; Presenilin-1; Rats; Rats, Wistar; Synaptosomes | 2009 |
Nitric oxide mechanism in protective effect of imipramine and venlafaxine against acute immobilization stress-induced behavioral and biochemical alteration in mice.
Topics: Animals; Antidepressive Agents; Anxiety; Arginine; Behavior, Animal; Cyclohexanols; Drug Synergism; Imipramine; Immobilization; Mice; Motor Activity; NG-Nitroarginine Methyl Ester; Nitric Oxide; Oxidative Stress; Pain Measurement; Stress, Psychological; Venlafaxine Hydrochloride | 2009 |
[Therapeutic effects of venlafaxine extended release for patients with depressive and anxiety disorders in the German outpatient setting - results of 2 observational studies including 8500 patients].
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Female; Germany; Humans; Male; Middle Aged; Outpatients; Prospective Studies; Psychiatric Status Rating Scales; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Venlafaxine involves nitric oxide modulatory mechanism in experimental model of chronic behavior despair in mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Arginine; Caffeine; Central Nervous System Stimulants; Chronic Disease; Cyclohexanols; Depressive Disorder; Disease Models, Animal; Enzyme Inhibitors; Male; Methylene Blue; Mice; Mice, Inbred Strains; Motor Activity; NG-Nitroarginine Methyl Ester; Nitric Oxide; Oxidative Stress; Random Allocation; Swimming; Venlafaxine Hydrochloride | 2010 |
The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids.
Topics: Animals; Anxiety; Behavior, Animal; Brain; Cannabinoids; Cyclohexanols; Disease Models, Animal; Dronabinol; Drug Tolerance; Exploratory Behavior; Genotype; Heterozygote; Male; Mice; Mice, Mutant Strains; Motor Activity; Neuregulin-1; Proto-Oncogene Proteins c-fos; Psychotropic Drugs; Reflex, Startle; Schizophrenia | 2011 |
Effect of anti-depressants on neuro-behavioural consequences following impact accelerated traumatic brain injury in rats.
Topics: Acceleration; Amitriptyline; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Brain Injuries; Bupropion; Citalopram; Cyclohexanols; Exploratory Behavior; Fear; Male; Neuronal Plasticity; Neurotransmitter Uptake Inhibitors; Norepinephrine; Rats; Rats, Wistar; Reflex, Startle; Serotonin; Social Behavior; Venlafaxine Hydrochloride | 2010 |
Cannabinoids increase conditioned ultrasonic vocalisations and cat odour avoidance in rats: strain differences in drug-induced anxiety.
Topics: Animals; Anxiety; Avoidance Learning; Cannabinoids; Cats; Conditioning, Psychological; Cyclohexanols; Male; Odorants; Rats; Rats, Inbred Lew; Rats, Wistar; Species Specificity; Ultrasonics; Vocalization, Animal | 2010 |
Organic cation transporter 2 controls brain norepinephrine and serotonin clearance and antidepressant response.
Topics: Action Potentials; Animals; Antidepressive Agents, Second-Generation; Anxiety; Brain; Corticosterone; Cyclohexanols; Depression; Disease Models, Animal; Female; Hippocampus; Limbic System; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Molecular Imaging; Norepinephrine; Organic Cation Transport Proteins; Organic Cation Transporter 2; Radioligand Assay; Serotonin; Venlafaxine Hydrochloride | 2012 |
Pregabalin and topiramate regulate behavioural and brain gene transcription changes induced by spontaneous cannabinoid withdrawal in mice.
Topics: Analysis of Variance; Animals; Anticonvulsants; Anxiety; Behavior, Animal; Body Temperature; Cannabinoids; Cyclohexanols; Dose-Response Relationship, Drug; Drug Tolerance; Fructose; gamma-Aminobutyric Acid; Male; Marijuana Abuse; Mice; Models, Animal; Motor Activity; Nucleus Accumbens; Pregabalin; Receptor, Cannabinoid, CB1; Receptors, Opioid, mu; Substance Withdrawal Syndrome; Topiramate; Transcription, Genetic; Tyrosine 3-Monooxygenase; Ventral Tegmental Area | 2013 |
Genetic vs. pharmacological inactivation of COMT influences cannabinoid-induced expression of schizophrenia-related phenotypes.
Topics: Alleles; Animals; Anxiety; Benzophenones; Benzoxazines; Biogenic Monoamines; Cannabinoid Receptor Agonists; Cannabinoids; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Chromatography, High Pressure Liquid; Cyclohexanols; Enzyme Inhibitors; Mice; Mice, Inbred C57BL; Mice, Knockout; Morpholines; Naphthalenes; Nitrophenols; Pain Measurement; Phenotype; Reflex, Startle; Schizophrenia; Schizophrenic Psychology; Social Behavior; Swimming; Tolcapone | 2012 |
Anxiolytic-like actions of reboxetine, venlafaxine and endurance swimming in stressed male rats.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Cyclohexanols; Male; Morpholines; Motor Activity; Physical Conditioning, Animal; Rats; Rats, Wistar; Reboxetine; Restraint, Physical; Stress, Physiological; Stress, Psychological; Swimming; Venlafaxine Hydrochloride | 2012 |
Chronic social defeat stress model: behavioral features, antidepressant action, and interaction with biological risk factors.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Cyclohexanols; Depression; Depressive Disorder; Disease Models, Animal; Fluoxetine; Male; Mice; Mice, Inbred C57BL; Risk Factors; RNA, Messenger; Social Behavior; Stress, Psychological; Thiazepines; Venlafaxine Hydrochloride; Vesicular Glutamate Transport Protein 1 | 2012 |
Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure.
Topics: Amidohydrolases; Amygdala; Animals; Anxiety; Arachidonic Acids; Chronic Disease; Cyclohexanols; Dendrites; Drug Evaluation, Preclinical; Endocannabinoids; Exploratory Behavior; Male; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Knockout; Polyunsaturated Alkamides; Pyramidal Cells; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Restraint, Physical; Stress, Psychological | 2013 |
Biphasic effects of cannabinoids in anxiety responses: CB1 and GABA(B) receptors in the balance of GABAergic and glutamatergic neurotransmission.
Topics: Animals; Anxiety; Behavior, Animal; Cannabinoids; Cyclohexanols; Cyclopentanes; Dose-Response Relationship, Drug; GABA Agonists; gamma-Aminobutyric Acid; Glutamic Acid; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Pyrimidines; Receptor, Cannabinoid, CB1; Receptors, GABA-B; Synaptic Transmission | 2012 |
Differences in clinician understanding and management of early menopause after breast cancer.
Topics: Anxiety; Australia; Breast Neoplasms; Cross-Sectional Studies; Cyclohexanols; Depression; Endocrinology; Exercise; Female; Follicle Stimulating Hormone; General Practitioners; General Surgery; Gynecology; Hot Flashes; Humans; Life Style; Medical Oncology; Menopause, Premature; Practice Patterns, Physicians'; Surveys and Questionnaires; Venlafaxine Hydrochloride | 2013 |
Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats.
Topics: Animals; Anxiety; Cannabinoids; Corticosterone; Cyclohexanols; Male; Maze Learning; Motor Activity; Narcotic Antagonists; Rats; Rats, Wistar; Receptors, Opioid, kappa | 2003 |
Venlafaxine: not yet first in the antidepressant class.
Topics: Antidepressive Agents, Second-Generation; Anxiety; Cyclohexanols; Humans; Remission Induction; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2003 |
Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55,940 in the social interaction test.
Topics: Animals; Anxiety; Cannabinoid Receptor Agonists; Conditioning, Operant; Cyclohexanols; Dose-Response Relationship, Drug; Interpersonal Relations; Male; Motor Activity; Rats; Receptors, Cannabinoid | 2004 |
Effects of nicotine and a cannabinoid receptor agonist on negative contrast: distinction between anxiety and disappointment?
Topics: Animals; Anxiety; Cannabinoid Receptor Agonists; Cannabinoids; Cyclohexanols; Emotions; In Vitro Techniques; Interpersonal Relations; Male; Maze Learning; Nicotine; Rats; Receptors, Cannabinoid | 2004 |
Drugs vs. talk therapy: 3,079 readers rate their care for depression and anxiety.
Topics: Antidepressive Agents; Anxiety; Anxiety Disorders; Bupropion; Citalopram; Cyclohexanols; Depression; Drug Therapy; Fluoxetine; Humans; Paroxetine; Patient Satisfaction; Primary Health Care; Psychiatry; Psychology; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Sertraline; Social Work | 2004 |
Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats.
Topics: Aging; Animals; Anxiety; Behavior, Animal; Cannabinoids; Cognition; Conditioning, Operant; Cyclohexanols; Dronabinol; Exploratory Behavior; Female; Hallucinogens; Interpersonal Relations; Learning; Memory Disorders; Memory, Short-Term; Motor Activity; Psychomotor Performance; Rats; Rats, Wistar | 2004 |
Bilateral acute angle closure caused by supraciliary effusions associated with venlafaxine intake.
Topics: Adult; Antidepressive Agents, Second-Generation; Antihypertensive Agents; Anxiety; Ciliary Body; Cyclohexanols; Depression; Glaucoma, Angle-Closure; Gonioscopy; Humans; Iris; Male; Microscopy, Acoustic; Ocular Hypertension; Venlafaxine Hydrochloride | 2005 |
Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anxiety; Ataxia; Behavior, Animal; Benzoxazines; Binding, Competitive; Catalepsy; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Cyclohexanecarboxylic Acids; Cyclohexanols; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Gabapentin; gamma-Aminobutyric Acid; Humans; Immunosuppressive Agents; Indoles; Indomethacin; Inflammation; Male; Mice; Mice, Knockout; Morpholines; Naphthalenes; Pain; Pain Measurement; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Reaction Time; Receptor, Cannabinoid, CB2; Time Factors | 2005 |
The four-plates test-retest paradigm to discriminate anxiolytic effects.
Topics: Adrenergic Uptake Inhibitors; Amphetamines; Animals; Anti-Anxiety Agents; Anxiety; Atropine; Avoidance Learning; Behavior, Animal; Benzodiazepines; Cholinergic Agents; Cyclohexanols; Discrimination, Psychological; Dose-Response Relationship, Drug; Male; Mice; Paroxetine; Receptors, GABA-A; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Agonists; Venlafaxine Hydrochloride | 2005 |
alpha2-Adrenergic agonists antagonise the anxiolytic-like effect of antidepressants in the four-plate test in mice.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Citalopram; Clonidine; Cyclohexanols; Cyclopropanes; Dose-Response Relationship, Drug; Drug Antagonism; Guanabenz; Male; Mice; Milnacipran; Motor Activity; Paroxetine; Punishment; Selective Serotonin Reuptake Inhibitors; Statistics, Nonparametric; Venlafaxine Hydrochloride | 2005 |
Persistent anxiogenic effects of a single or repeated doses of cocaine and methamphetamine: interactions with endogenous cannabinoid receptor ligands.
Topics: Analysis of Variance; Animals; Anxiety; Arachidonic Acids; Behavior, Animal; Cannabinoids; Cocaine; Cyclohexanols; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Endocannabinoids; Glycerides; Injections, Intraperitoneal; Male; Maze Learning; Methamphetamine; Mice; Mice, Inbred ICR; Polyunsaturated Alkamides; Receptor, Cannabinoid, CB1; Time Factors | 2005 |
Tension-type headache with aura.
Topics: Adrenergic Uptake Inhibitors; Amitriptyline; Anti-Anxiety Agents; Anticonvulsants; Anxiety; Bromazepam; Cyclohexanols; Fructose; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; Tension-Type Headache; Topiramate; Venlafaxine Hydrochloride; Vision Disorders | 2006 |
Repeated cannabinoid exposure during perinatal, adolescent or early adult ages produces similar longlasting deficits in object recognition and reduced social interaction in rats.
Topics: Aging; Animals; Animals, Newborn; Anxiety; Cannabinoid Receptor Agonists; Cannabinoids; Cognition Disorders; Cyclohexanols; Exploratory Behavior; Interpersonal Relations; Male; Memory; Memory, Short-Term; Motor Activity; Rats; Rats, Wistar; Recognition, Psychology | 2006 |
Venlafaxine reverses chronic fatigue-induced behavioral, biochemical and neurochemical alterations in mice.
Topics: Adrenergic Uptake Inhibitors; Animals; Anxiety; Behavior, Animal; Cyclohexanols; Disease Models, Animal; Dopamine; Fatigue Syndrome, Chronic; Glutathione; Lipid Peroxidation; Male; Maze Learning; Memory; Mice; Motor Activity; Norepinephrine; Oxidative Stress; Selective Serotonin Reuptake Inhibitors; Serotonin; Venlafaxine Hydrochloride | 2008 |
Venlafaxine withdrawal reactions.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Cyclohexanols; Depression; Depressive Disorder; Dizziness; Fatigue; Female; Hallucinations; Headache; Humans; Male; Middle Aged; Nausea; Sensation Disorders; Substance Withdrawal Syndrome; Tinnitus; Venlafaxine Hydrochloride | 1998 |
Effect of venlafaxine on the pharmacokinetics of risperidone.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety; Area Under Curve; Cyclohexanols; Desvenlafaxine Succinate; Exploratory Behavior; Female; Humans; Isoxazoles; Male; Metabolic Clearance Rate; Middle Aged; Paliperidone Palmitate; Psychomotor Performance; Pyrimidines; Risperidone; Venlafaxine Hydrochloride | 1999 |
Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters.
Topics: Analgesics; Animals; Anxiety; Cannabinoids; Cyclohexanols; Drug Therapy, Combination; Exploratory Behavior; Hypothalamus; Male; Motor Activity; Neurotransmitter Agents; Piperidines; Pyrazoles; Rats; Rats, Wistar; Rimonabant | 2001 |
Treatment costs of venlafaxine and selective serotonin-reuptake inhibitors for depression and anxiety.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Cyclohexanols; Depressive Disorder; Drug Costs; Female; Health Care Costs; Humans; Longitudinal Studies; Male; Managed Care Programs; Middle Aged; Patient Compliance; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; United States; Venlafaxine Hydrochloride | 2002 |
Inhibition by venlafaxine of the increase in norepinephrine output in rat prefrontal cortex elicited by acute stress or by the anxiogenic drug FG 7142.
Topics: Animals; Anxiety; Carbolines; Cyclohexanols; Dose-Response Relationship, Drug; Electroshock; Extracellular Space; GABA Agonists; Male; Microdialysis; Norepinephrine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Stress, Psychological; Venlafaxine Hydrochloride | 2002 |